RegCell Scientific Founder and Board Member Dr. Shimon Sakaguchi Awarded Nobel Prize in Physiology or Medicine

EMERYVILLE, Calif., Oct. 9, 2025 /PRNewswire/ -- RegCell, Inc. a biotechnology company developing first-in-class therapies for autoimmune diseases and transplantation with its epigenetic reprogramming platform leveraging the natural biology of regulatory T cells (Tregs), proudly announced that Dr. Shimon Sakaguchi, Distinguished Professor of Osaka University, Professor Emeritus of Kyoto University, scientific founder of the company and member of its Board of Directors, has been awarded the 2025 Nobel Prize in Physiology or Medicine for the groundbreaking discovery of regulatory T cells (Tregs) and their essential function in maintaining immunological self-tolerance.

The Nobel Assembly at the Karolinska Institute recognized Dr. Sakaguchi and his colleagues, Dr. Mary E. Brunkow and Dr. Fred Ramsdell, for their research that advanced our understanding of how the immune system differentiates between pathogenic invaders and the body's own cells, knowledge that has profoundly influenced the field of immunology and is critical for preventing and treating autoimmune diseases and for improving the success of organ transplants. Dr. Sakaguchi discovered previously unknown Tregs in 1995 and later demonstrated that the Foxp3 gene governs their development.

"We are deeply honored to count on Dr. Sakaguchi as a scientific founder of RegCell and among our board members," said Dr. Michael McCullar, Chief Executive Officer of RegCell. "This award is further validation of the promise of his scientific vision and commitment to advancing human health and exemplifies the spirit of innovation that drives our mission to serve patients by developing groundbreaking immunological therapies for autoimmune disease and transplantation."

RegCell's Co-Founder and Nobel Prize awardee, Professor Shimon Sakaguchi, stated, "I am deeply humbled by this honor and inspired that the discoveries from our work, alongside those of Dr. Brunkow and Dr. Ramsdell, have contributed to advancing medicine in ways that may one day improve the lives of people affected by autoimmune disease and in need of transplantation across the globe."

About RegCell 

RegCell is a global biotechnology company based in the U.S. and built on the pioneering discoveries of Co-Founder Professor Shimon Sakaguchi in regulatory T-cell biology. RegCell is pioneering cell therapies for autoimmune diseases and transplantation. RegCell has developed a best-in-class proprietary platform to generate stable, epigenetically reprogrammed, antigen-specific Tregs that can restore antigen-specific immune tolerance. By addressing unknown or multiple pathogenic antigens, RegCell's platform overcomes key limitations that have thus far prevented the development of cell therapies for autoimmune diseases. These conditions are typically managed with drugs that broadly suppress the immune system, cannot distinguish disease-causing immune cells from healthy ones, and do not target the underlying cause. RegCells' approach does not require genetic modifications, allowing for simplified manufacturing, enhanced safety, and expanded scalability to address a broad spectrum of autoimmune patients. Driven by a vision to redefine self-tolerance, RegCell is committed to delivering safe, life-changing cell therapies that can reverse autoimmune disorders and overcome challenges in transplantation. 

For more information, visit http://www.regcellbio.com/ and follow us on LinkedIn and Twitter.

Media Contact: 

Ignacio Guerrero-Ros, Ph.D., or Rob Haney, Ph.D.
Russo Partners LLC
[email protected] 
[email protected] 

Investor Contact:

James Ahlers
RegCell, Inc.
[email protected]

SOURCE RegCell, Inc.